| Literature DB >> 26703591 |
Yongliang Wang1, Xinyi Liu2, Liming Hou3, Wangjun Wu4, Shuhong Zhao5, Yuanzhu Xiong6.
Abstract
Fibroblast growth factor 21 (FGF21) plays an important role in the treatment of disease associated with muscle insulin resistance which is characterized by various factors, such as intramuscular triglyceride (IMT) content. Studies have also shown that FGF21 inhibits triglyceride synthesis in vivo. However, the precise mechanism whereby FGF21 regulates triglyceride metabolism in intramuscular fat (IMF), which may influence the muscle insulin sensitivity, is not clearly understood. In order to understand the role of FGF21 in IMF deposition, we performed FGF21 overexpression in IMF cells by stable transfection. Our results showed that FGF21 inhibited the key adipogenesis gene mRNA expression of peroxisome proliferator-activated receptor gamma (PPARG), CCAAT/enhancer-binding protein (CEBP) family by reducing lysine-specific demethylase 1 (LSD1) expression which led to significant decline in lipid accumulation, and the result was confirmed by Western blot. Moreover, triggered by FGF21, parts of the adipokines--fatty acid-binding protein 4 (FABP4), glucose transporter 4 (GLUT4), adiponectin (ADIPOQ), and perilipin (PLIN1)--were also down-regulated. Furthermore, FGF21 gene expression was suppressed by transcription factor CEBP beta (CEBPB) which contributed strongly to triglyceride synthesis. Taken together, our study is the first to experimentally demonstrate FGF21 emerging as an efficient blockade of adipogenesis in IMF, thus also providing a new understanding of the mechanism whereby FGF21 improves insulin sensitivity.Entities:
Keywords: CEBPB; FGF21; IMT; adipogenesis; pig
Mesh:
Substances:
Year: 2015 PMID: 26703591 PMCID: PMC4730258 DOI: 10.3390/ijms17010011
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Expression profiles analysis of FGF21. The relative expression of FGF21 in heart, liver, spleen, lung, kidney, brain, small intestine, stomach, longissimus dorsi and subcutaneous fat in three-month Large White pigs and the mRNA level was normalized with glyceraldehydes phosphate dehydrogenase (GAPDH).
Figure 2Morphology of the primary cultured cells. (A) Morphology of primary cultured pig intramuscular fat cells on the 3rd day (bar = 200 μm); (B) Morphology of primary cultured pig intramuscular fat cells on the 8th day (bar = 200 μm); and (C) Lipid droplets became jacinth colored by oil red O (bar = 200 μm).
Figure 3FGF21 expression in the FGF21 stable monoclone (FM) cells before cell differentiation. (A) qRT-PCR analysis revealed that FM cells had higher FGF21 mRNA level than that in the control; and (B) Western blot analysis showed that the FGF21 protein level was up-regulated significantly in FM cells. Gene expression was normalized to GAPDH. Data was presented as mean ± SD, *** for p < 0.001.
Figure 4FGF21 suppressed the accumulation of triglycerides. Oil red staining results showed less lipid droplets in FM cells (left) than that in the control (right) (bar = 100 μm). The arrows indicated the lipid.
Figure 5FGF21 reduced the adipogenesis-related genes expression on the cell differentiation 8th day. The qRT-PCR analysis of CEBP family and PPARG (A); The genes expression regulating CEBP family and PPARG (B); adipokines (C); Wnt signal (D); HDAC family (E) and FGFRs signal (F) on the cell differentiation 8th day. Gene expression was normalized with GAPDH. Data was presented as mean ± SD, * for 0.01 < p < 0.05, ** for 0.001 < p < 0.01 and *** for p < 0.001; Western blot analysis of the adipogenesis-related genes on the cell differentiation 8th day. The gene expression was normalized with ACTIN (G) and GAPDH (H).
Figure 6Methylation analysis of CEBPA promoter. No significant difference of methylation level between FM and the control was found in the region from −172 to +2 bp in CEBPA promoter with the Quantification Tool for Methylation Analysis on line.
Figure 7The transcription factor CEBPB suppressed FGF21 expression by binding to FGF21 promoter. QRT-PCR analysis showed CEBPB reduced FGF21 mRNA level. ** for 0.001 < p < 0.01 (A); The electrophoretic mobility shift assay (EMSA) was used to simulate the binding of CEBPB with FGF21 promoter in vitro (B); The chromatin immunoprecipitation (CHIP) assay was performed to detect the binding of CEBPB with FGF21 promoter in vivo (C), total chromatin and normal mouse IgG were used as the input and the negative control respectively.
Figure 8The proposed mechanism of FGF21 action in triglyceride metabolism. Briefly, FGF21 suppressed adipogenesis by reducing LSD1 expression, and in the meantime, FGF21 expression was repressed by the transcription factor CEBPB. The red line represented for the action of inhibition and the green line represented for the action of activation.
Primer Sequences for qRT-PCR.
| Genes | Primer Sequences (5′–3′) | Length of Amplicon (bp) |
|---|---|---|
| F: ACTGTGGGTCCCTGTGCTG | 118 | |
| F: TCCCGCTGACCAAAGCAAAGGC | 195 | |
| F: GAAAGTCAAGAGCACGATAACC | 124 | |
| F: TTACACCTCCCTCAACTTCCG | 153 | |
| F: GTCTTTGCGGGTATTCGG | 228 | |
| F: TGCCTTTGGTTCTGGTGG | 354 | |
| F: TAACGAACCCGACCAGCATC | 140 | |
| F: GAATCGGAGGCTACAAGGTC | 305 | |
| F: CTGCCGCCAACTCTGTCA | 165 | |
| F: TCATCCTGTCACCGTTTATTC | 169 | |
| F: CGGTGCGTCTAAGATGAGG | 120 | |
| F: AGCCTGTCCACATCCTCG | 135 | |
| F: TCAAACACGCCGAACTACAC | 207 | |
| F: TGTTGCGGATGCTATGGG | 169 | |
| F: CTGGCGAGAAGAGTGAGA | 158 | |
| F: GTTCGTCCGCTCCTACAA | 112 | |
| F: GTGCCAGGAACAGCAACAG | 194 | |
| F: AAGACCGCTTTACAAGTGCC | 200 | |
| F: AGCCAGTTGACAGTGAGGAAT | 109 | |
| F: GCAGGGTGGAATGAATGTG | 150 | |
| β
| F: AAGCAGGTGGATCTATTTCATG | 159 |
| F: GGGCATGAACCATGAGAAGT | 230 | |
| F: GGCGAGAAGCCCTAACACT | 121 | |
| F: CGCACAGATGGCATTGGA | 184 | |
| F: CGGAGGGAGACGGAGGAGTT | 108 | |
| F: GAAGGGTGCGACTGGAGGTT | 133 | |
| F: CAAGGCCATAGTCCTGTTCACC | 101 |
The primers of SIRT1 and SIRT2 are referred to in the literature [49], and for the HDAC family, please see our laboratory published date [50], F for forward and R for reverse.